AUT00201 boosts muscle strength, coordination in ALS mouse model
AUT00201, an experimental oral small molecule being developed by Autifony Therapeutics, reduced the loss of motor neurons — the…
Articles by Margarida Maia, PhD
Longitude Prize on ALS encourages use of AI to find new treatments
The Longitude Prize on ALS is offering a total of £7.5 million (more than $10 million) to encourage scientists…
Thousands in US use ALS treatment Radicava ORS, company says
Three years after its approval in the U.S., Radicava ORS (edaravone) has been prescribed by more than 1,300 healthcare…
Psychiatric medications linked to increased ALS risk, worse outcomes
People prescribed common psychiatric medications had a higher risk of developing amyotrophic lateral sclerosis (ALS) and saw worse outcomes…
New ALS scholarship supports US students facing financial barriers
The Everylife Foundation for Rare Diseases is offering a new scholarship for students from the amyotrophic lateral sclerosis…
Transposon’s TPN-101 selected for testing in HEALEY ALS trial
Oral small molecule TPN-101 has been selected for testing in amyotrophic lateral sclerosis (ALS) as part of the HEALEY ALS platform…
FDA clears Phase 3b trial of NurOwn for ALS
The U.S. Food and Drug Administration (FDA) has cleared a Phase 3b clinical trial to test Brainstorm Cell Therapeutics’ cell-based…
Bacteria mix to aid gut microbiome may slow ALS progression
MaaT033, an oral therapy aiming to restore balance to the collection of bacteria and other microbes in the gut, was…
Young investigators receive MGH awards for ALS research
Three researchers at Massachusetts General Hospital (MGH) have received 2025 MGH ALS Young Investigator Awards for their research on genetic…
Real-world Radicava use in ALS tied to unexpected side effects: Data
The real-world use of Radicava (edaravone), an infusion treatment approved for amyotrophic lateral sclerosis (ALS), may cause serious…